BEIJING, May 20 -- China's health authority on Friday announced cuts of over 50 percent in the prices of three patent drugs.
The National Health and Family Planning Commission said through pharmaceutical manufacturers have agreed to lower some drugs' prices on condition of bulk purchase.
GlaxoSmithCline (GSK) will reduce the price of Tenofovir Disoprox, a treatment for hepatitis B, from 1500 yuan (229 U.S.dollars) to 490 yuan per month.
Icotinib, an anti-cancer drug made by China's Betta Pharmaceuticals, will be dropped from 12,000 yuan to 5,500 yuan for a month's supply.
AstraZeneca will lower the monthly cost for the anti-cancer Gefitinib from 15,000 yuan to 7,000 yuan.
High prices of imported and patent drugs are a great burden for Chinese patients and the country as a whole.
French girl ties the knot with Chinese boy
Beijing Style: ready for bare legs
Century-old station sees railyway evolution
Enthusiasts perform Kung Fu at Wudang Mountain
Stunning photos of China's fighter jets in drill
Monk's mummified body to be made into a gold Buddha statue
Former Chinese solider of the French Foreign Legion seeks wife online
Asia's longest and highest suspension bridge to open to traffic
China's first interactive robot looks like a beauty
Top 20 hottest women in the world in 2014
Top 10 hardest languages to learn
10 Chinese female stars with most beautiful faces
China’s Top 10 Unique Bridges, Highways and Roads
Hong Kong opposition should seize the moment
Trump’s anti-immigrant rhetoric strikes a chord with Chinese Americans
China rejects latest US steel measures
Is the wage gap between expats and locals a function of the market – or plain old discrimination?Day|Week
